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Key messages: 
1. JAKi selectively is relative and not absolute. 
2. Current approved JAKi and those in development significantly inhibit JAK1 isoform.  
3. JAK1 is an effective target in RA although zoster reactivation is a class effect. 
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Abstract 
 
Cytokines are key drivers of inflammation in rheumatoid arthritis (RA). Anti-cytokine therapy 
has improved the outcome of RA. Janus kinases (JAK) are intracellular tyrosine kinases 
linked to intracellular domains of many cytokine receptors. There are four JAK isoforms: 
JAK1, JAK2, JAK3 and TYK2. Different cytokine receptor families utilise specific JAK isoforms 
for signal transduction. Phosphorylation of JAK when cytokine binds to its cognate receptor 
leads to phosphorylation of other intracellular molecules that eventually leads to gene 
transcription. Oral JAK inhibitors have been developed as anti-cytokine therapy in RA. Two 
JAK inhibitors, tofacitinib and baricitinib. have been approved recently for the treatment of 
RA. Many JAK inhibitors are currently in development. JAK inhibitors inhibit JAK isoforms 
with different selectivity. This review discusses efficacy and safety of JAKi in RA in particular 
the potential clinical significance of JAKi selectivity. 
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Background 
During the 1990s, when monoclonal antibodies (mAbs) were trialled in patients with 
Rheumatoid Arthritis (RA), many rheumatologists questioned whether intravenous or 
subcutaneous injections could ever be a realistic treatment. At the time, researchers argued 
that the mAbs were the ideal tools to identify specific therapeutic targets for which oral 
inhibitors can be developed.  This vision was realised when in 2009 the Food and Drug 
Administration approved the first Janus Kinase Inhibitors (JAKi), tofacitinib, for the 
treatment of RA. In 2017, tofacitinib and another JAKi, baricitinib, received approval in  
Europe. Janus Kinases (JAKs) are intracellular molecules involved in signal transduction of 
type I and II cytokine receptors1 including interleukin (IL)-6 receptor, a proven therapeutic 
target in RA2. JAKi are classified by European League Against Rheumatism (EULAR) as 
targeted synthetic Disease Modifying Anti-Rheumatic Drugs (tsDMARDs). There are 4 JAK 
isoforms: JAK1, JAK2, JAK3 and TYK2, which act in pairs to phosphorylate other intracellular 
proteins. Other JAKi are being developed for the treatment of RA. Current JAKi, approved 
and in development for RA, inhibit JAK isoforms with different selectivity. Is JAK selectivity 
clinically meaningful? This review will discuss efficacy and safety of JAKi in RA as well as 
potential clinical significance of JAK isoform selectivity. 
 
Cytokine signalling and Biology of JAK/STAT pathway 
Cytokines can be classified by the structure of their receptors. Type I cytokine receptors 
have certain conserved motifs in their extracellular amino-acid domain. These include 
common γ chain (such as IL-2), gp130 family (such as IL-6), p40 subunit (IL-12 and IL-23), and 
common  chain cytokine receptors (haemopoietic cytokines such as GM-CSF). Type 2 
cytokine receptors are members of the IL-10 and interferon families. Both Type I and II 
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cytokine receptor families utilise the JAK for signalling transduction. Among these cytokines 
and cytokine receptors, IL-6 and IL-6R are established therapeutic targets in RA. The role of 
other JAK signalling cytokines in RA is less well established. JAKs also have essential 
homeostatic roles, being responsible for signalling of some hormones including prolactin 
and growth hormone (GH). 
 
JAKs are associated with the membrane proximal regions of cytokine receptors3. 
Conformational changes in cytokine receptors induced by ligand binding lead to 
phosphorylation of JAKs through the reciprocal interaction of two juxta-positioned JAKs 
(Figure 1). Hence, JAKs activation requires two JAK isoforms either as homodimers or 
heterodimers to auto-phosphosphorylate, which allows recruitment and phosphorylation of 
various signalling molecules including members of the signal transducer and activator of 
transcription (STAT) family of DNA binding proteins4. Phosphorylation of STATs promotes 
their translocation to the nucleus and gene transcription. 
 
Since, type I and II cytokine receptor families include a large number of cytokines, growth 
factors and hormones, JAKs are critical to immune function and homeostasis. Consequently, 
JAKs are highly conserved and JAK isoforms are non-redundant. JAK isoform knock-out 
animals have severe clinical phenotypes: JAK15 deficient mice die perinatally while JAK2 
knockout animals are embryonic lethal due to defective erythropoiesis6. JAK37 deficient 
mice suffer from severe immunodeficiency syndrome and reduced survival. In humans, 
mutations in JAK3 cause severe combined immune deficiency syndrome8,9. TYK2 deficient 
mice are viable but susceptible to viral infection due to reduced interferon response10.  
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Therapeutic Principle of JAK Inhibition 
Evidence from animals and patients with JAK isoform deficiency showed that complete 
blockade of JAK isoforms is undesirable as it will lead to severe immunodeficiency and 
abnormal homeostasis. Therefore, the principle of JAKi inhibition differs from cytokine 
inhibition using biologics in that the objective is not to block specific JAK pathway 
completely but reversibly reduce the activity of one or more JAK isoforms akin to turning 
down of a thermostat. One potential clinical advantage of such mode of action is that 
inhibition can be rapidly reversed with “fast-on” and “fast-off” effects.  
 
JAK Inhibitors 
Two JAKi, tofacitinib and baricitinib, in combination with methotrexate (MTX) or as 
monotherapy, have been approved for the treatment of RA. Both tofacitinib and baricitinib 
have been examined in large phase III and IV randomised control trials (RCT) in a range of RA 
patients from csDMARD naïve early patients, csDMARD inadequate responders (IR) to 
biologic IR. The American College of Rheumatology (ACR) responses in these studies are 
summarised in Table 1.  Tofacitinib is selective for JAK1 for JAK3 while baricitinib is selective 
for JAK1 and JAK2. In addition, four JAKi are currently in development: the JAK1 selective: 
upadacitinib and filgotinib, JAK1 and JAK2 inhibitor: peficitinib, and JAK3 selective inhibitor: 
decernotinib. 
 
In MTX IR, tofacitinib (5 and 10mg bd) in Oral-STANDARD11 and baricitinib (4mg od) in RA-
BEAM12 added to MTX showed superior ACR responses when compared to placebo. 
Tofacitinib showed a similar response to adalimumab while baricitinib in RA-BEAM achieved 
statistically significant higher ACR20 responses than adalimumab (70% vs 61%). However, 
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the difference was small (<10%) and the sample size was larger in RA-BEAM than Oral-
STANDARD. Similar to MTX IR, in csDMARD IR, adding tofacitinib in Oral-SYNC13 and 
baricitinib in RA-BUILD14 achieved higher ACR responses than placebo. In biologic IR, 
tofacitinib (5 and 10mg bd) in Oral-Step15 and baricitinib (2 and 4mg od) in RA-BEACON16 in 
combination with MTX achieved higher ACR responses than placebo.  
 
Radiographic damage 
In ORAL- SCAN17, radiographic damage was statistically significantly less in patients treated 
with tofacitinib 10 mg when compared to placebo-treated patients. Tofacitinib 5 mg treated 
patients had less radiographic damage than placebo-treated patients but this did not 
achieve statistical significance. Baricitinib has also been shown to reduce radiographic 
damage in RA-BUILD14, RA BEAM12 and RA-BEGIN18. In RA-BUILD, baricitinib, both 2 and 4mg 
in combination with MTX statistically significantly reduced radiographic progression when 
compared with placebo. In RA-BEGIN, baricitinib 4mg monotherapy treated patients had 
less radiographic progression than placebo but the difference was not statistically significant. 
 
Monotherapy versus combination therapy with MTX 
Since JAKi are not bDMARDs, they do not incite anti-drug antibody response so theoretically 
concomitant treatment with MTX should be unnecessary.  Tofacitinib monotherapy was 
assessed in Oral SOLO19 and Oral START20 while baricitinib monotherapy was assessed in RA-
BEGIN18. Tofacitinib (5 and 10mg) and baricitinib 4mg monotherapy were superior to MTX. 
Barcitinib monotherapy produced similar therapeutic response to 4mg plus MTX. However, 
the sample size of the study was not powered to compare difference between monotherapy 
versus combination therapy. Indeed, the sample size of the monotherapy was smaller 
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(N=159) than the MTX plus baricitinib group (N=215). Furthermore, both Oral-START and 
RA-BEGIN were trials of patients with early RA while in routine clinical practice, JAKi are 
used in patients with established disease. These studies showed than JAKi monotherapy is 
effective, but it is unclear whether monotherapy is as effective as combination therapy. For 
tofacitinib, this was assessed in ORAL-STRATEGY21, a 1-year, double-blind, head-to-head, 
non-inferiority, RCT comparing tofacitinib (5 mg bd) monotherapy, tofacitinib (5 mg bd) plus 
MTX, and subcutaneous adalimumab (40 mg fortnightly) plus MTX in MTX IR patients. The 
primary endpoint was ACR50 response at month 6. This was met by 38%, 46% and 44% of 
patients in tofacitinib monotherapy, tofacitinib plus MTX and adalimumab plus MTX 
respectively. Tofacitinib plus MTX was non-inferior to adalimumab plus MTX but non-
inferiority was not demonstrated in the tofacitinib monotherapy group suggesting that in 
patients who can tolerate MTX, combining tofacitinib with MTX is better than switching to 
monotherapy. 
 
JAKi in development 
Phase II RCT data of upadacitinib22,23, filgotinib24,25, peficitinib26,27 and decernotinib28,29 are  
summarised in Table 2. Overall, these JAKi demonstrated superior ACR responses than 
placebo-treated group. Recently, phase III trials of upadacitinib in csDMARD IR (SELECT 
Next)30 and biologic IR (SELECT Beyond)31 patients have been published which confirmed 
efficacy of updacitinib (15 and 30mg od). 
 
Safety profile of JAKi 
Safety data on JAKi are mostly based on RCT and extension studies. Limited real-world data 
are available for tofacitinib32. Caution should be exercised when comparing incidence rate 
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(IR) of adverse event with biologic agents, in which IR from real-world data33 are available.  
In pooled analyses, the IR of serious adverse events was 9.4/100pyrs (95%CI 9.0-0.9) for 
tofacitinib34. For baricitinib, the IR of severe adverse event has not been reported but IR of 
specific adverse events are available. The key adverse event data on tofacitinib and 
baricitinib are summarised in table 3. 
 
Infections 
The IR of serious infections was 2.7/100pyrs (95%CI 2.5-3.9)34 and 2.9/100pyrs (95%CI 2.5-
3.4)35 for tofacitinib and baricitinib respectively.  Both tofacitinib and baricitinib were 
associated with increased incidence of reactivation of herpes zoster (3-4/100pyrs). This was 
higher than placebo and exceeded those expected with biologic agents. Risk was highest in 
Japan and Korea36. Concomitant glucocorticoid was an additional risk factor. Reactivation of 
herpes zoster appears to be a class effect and may be due to inhibition of interferon and IL-
15 which are key anti-viral cytokines which signal through JAK1, JAK2 and JAK3. Response to 
zoster vaccine prior to JAKi treatment has been evaluated in a RCT37. Zoster vaccine was 
given to 112 patients with active RA taking MTX 2 weeks before receiving either placebo or 
tofacitinib for 12 weeks, after which placebo-treated patients received tofacitinib in an 
open-label extension study. Both humoral and cellular immune responses to the zoster 
vaccine were similar in placebo and tofacitnib-treated patients. In the open-label extension 
phase, 5 patients developed reactivation of zoster. All these patients had suboptimal 
vaccine immune response to the zoster vaccine.  
 
Malignancies 
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IR of malignancies excluding non-melanoma skin cancer for tofacitinib34 and baricitinib35 was 
0.9/100pyrs (95%CI 0.8-1) and 0.8/100pyrs (95%CI 0.6-1.0) respectively. IR for lymphoma 
was 0.1/100pyrs (95%CI 0.1-0.2) for tofacitinib and 0.09/100pyrs (95%CI 0.03-0.19) for 
baricitinib. Non-melanoma skin cancer occurred in 0.6/100pyrs (95%CI 0.5-0.7) for 
tofacitinib and 0.4/100pyrs (95%CI 0.2-0.5) for baricitinib. However, long-term real-life data 
will be needed to assess accurately the risk of malignancies. 
 
Gastrointestinal perforation 
Gastrointestinal perforation is associated with IL-6 inhibition. IL-6 signals via JAK1, JAK2 and 
TYK2. Therefore, inhibiting IL-6 signalling by JAKi may be associated with gastrointestinal 
perforation. IR of gastrointestinal perforation was 0.11/100pyrs (95%CI 0.07-0.17) for 
tofacitinib and 0.05/100pyrs (95%CI 0.01-0.13) for baricitinib. These were numerically lower 
than that was observed with tocilizumab reported in registry which was 0.27/100 patient 
year38. Indeed, a real-world study also suggested the same. Lower gastrointestinal tract 
perforation was slightly less frequent in tofacitinib-treated than tocilizumab-treated 
patients, although these are higher than patients treated by TNF inhibitors39 
 
Deep vein thrombosis (DVT) and pulmonary embolus (PE) 
Five cases of DVT and/PE was observed with baricitinib (IR 1.2/100pyrs) but none in the 
placebo-treated patients during RCTs40. Overall IR of DVT/PE was 0.5/100pyrs (95%CI 0.3-
0.7). There was no association between platelet count and the occurrence of DVT/PE. IR of 
DVT and PE associated with tofacitinib has not been reported. However, as these adverse 
events are uncommon, data from registries will be needed to evaluate the association 
between DVT/PE and JAKi. 
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Laboratory abnormalities 
Haemoglobin (Hb) 
One of the extra-articular features of active RA is anaemia of chronic diseases, which is 
mediated by hepcidin as part of the acute-phase response2. Hence, effective suppression of 
inflammation should increase Hb which has been with biologic treatment41,42. However, 
haemopoietic cytokines including erythropoietin signals via JAK243. A consequence of JAK2 
inhibition is reduced erythropoiesis. This is reflected by Hb changed associated with 
baricitinib44 in which, there was a statistically significant greater reduction (p=0.02) in Hb 
occurred with baricitinib -0.17+0.02 when compared to placebo-treated patients -0.12+0.02. 
Anaemia occurred in 29% of baricitinib-treated versus 26% in placebo-treatment patients. In 
contrast, a small increase in Hb was observed in a pooled analysis of tofacitinib which has 
less inhibitory effect on JAK2: 0.47 g/dl and 0.28 g/dl with 5 and 10 mg respectively45. The 
likely reason for a smaller increase in Hb with tofacitinib 10mg is dose-associated inhibition 
of JAK2 i.e. at low dose (5mg) tofacitinib is selective for JAK1 and JAK3 but at 10mg, this 
selectivity is diminished and JAK2 is inhibited. Compared to MTX, both doses of tofacitinib 
were associated with a slightly higher incidence of anaemia although in total  <1% of 
patients experienced major decrease in Hb as defined by decrease from baseline of >3 g/dl 
or an absolute haemoglobin level of >7 g/dl. Nevertheless, Summary of Product 
Characteristics (SPC) recommended tofacitinib46 and baricitinib47 should not be used in 
patients who are anaemic (Hb<8g/dl) and treatment should be interrupted when Hb drops 
below 8g/dl. 
 
Neutrophil 
 11 
Decrease in neutrophil count with occasional cases of neutropenia (Table 3) has been 
observed with all JAKi. SPCs recommend monitoring of neutrophil count in patients taking 
JAKi46,47. 
   
Lymphocyte 
Lymphopenia can occur in patients treated with JAKi. For tofacitinib, lymphopenia <500 
cells/mL occurred in 8.3/100pyrs (95%CI 3.0-18.1)45. Multivariate analysis suggested 
lymphocyte count <500cells/mL was associated with increased risk of serious infection34. 
Lymphopenia was uncommon (<1% of patients) but has also been observed after treatment 
with baricitinib48. The presence of lymphopenia was associated with a slightly higher overall 
infection rate, but not for serious infections. Although the lack of association with serious 
infection may be due to insufficient event and patient number. SPCs recommend 
interrupting JAKi treatment when lymphocyte count is <500cells/ml46,47. 
 
Platelet 
Thrombocytosis is a feature of active disease in RA2. Suppression of inflammation should 
reduce platelet number. Surprisingly, treatment by baricitinib was associated with 
thrombocytosis48. Increases in platelet counts above 600x109 cells/L occurred in 2.0% of 
patients compared with 1.1% of placebo-treated patients47. There is no published data on 
change in platelet count after treatment with tofacitinib.  
  
Biochemistry 
Lipids 
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Increase in both high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol 
occurred after treatment with both tofacitinib49 and baricitinib50 although there is no 
change in HDL/LDL ratio. IR of major adverse cardiovascular events was 0.58/100 patients 
years (95%CI 0.39-0.88) for tofacitinib51 and 0.5/100 pyrs (95%CI 0.4-0.7] for baricitinib48. A 
mechanistic study examined the effect of tofacitinib on cholesterol and lipoprotein 
transport showed that HDL, LDL and total cholesterol levels were lower in 
RA patients than in healthy volunteers while cholesterol ester fractional catabolic 
rate was higher in RA patients52 suggesting cholesterol catabolism is increased. Treatment 
with tofacitinib reduced inflammation and restored cholesterol catabolism.  
 
Liver transaminases 
Increases in liver transaminases (>3x ULN) occurred in up to 2% of patients receiving 
tofacitinib53 and 1.4% of patients treated with baricitinib47. Most cases were transient and 
asymptomatic. Liver function tests should be monitored in patient taking JAKi and when 
liver transaminases increase significantly, treatment should be temporarily discontinued.  
 
Increase in creatinine levels 
Small increase in serum creatinine by 2-4 µmol/L was observed in RCTs when compared 
with placebo for tofacitinib54 and baricitinib55. This plateaued after 3 months and was not 
associated with significant renal side effects. 
 
Increase in creatine phosphokinase (CPK) 
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Increase in CPK (>5 x the upper limit of normal) occurred in up to 1% of patients treated 
with either tofacitinib46 or baricitinib47. In most cases, CPK elevation was transient, 
asymptomatic and did not require treatment discontinuation.  
 
Safety of JAKi in development 
Exposure is too low to assess major clinical safety such as serious infection. For laboratory 
measures, changes in biochemistry measures have been observed with all JAKi suggesting 
that these are class effects (Table 3).  
 
For haematology measures, decrease in neutrophil and lymphocyte count including 
neutropenia and lymphopenia, have been observed with all JAKi suggesting these are also 
class effects. However, JAKi have different effects on Hb and platelet count.  Filgotinib and 
decernotinib increased Hb but peficitinib and upadacitinib especially at high doses 
decreased Hb. Therefore, filgotinib and decernotinib are similar to tofacitinib while 
peficitinib and upadacitinib are more akin to baricitinib. The most likely explanation for 
these differences is inhibition of JAK2 which is expected with in vitro profile of baricitinib 
and peficitinib. Another potential differentiating feature among JAKi is the effect on platelet 
count, both filgotinib and peficitinib decrease platelet numbers while baricitinib increased 
platelet number. Effect of upadacitinib and decernotinib on platelet number was not 
reported. 
 
JAK isoform Selectivity 
Structurally, JAKs are composed of seven homologous regions JH1-7. JH5-7 are critical for 
the association of the JAKs with their cognate receptors while JH1 kinase is the active 
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catalytic domain and the main target for JAKi. Because the JH1 domains of the JAK isoforms 
exhibit a high degree of homology, JAKi are selective but not specific.  
JAKi selectivity is assessed by in vitro assay of cytokine release and/or pSTAT activation. It is 
important to note that results from these assays depend on assay substrates/cell lines and 
cytokines measured. Furthermore, JAK1, JAK2 and TYK2 are ubiquitously expressed but  
JAK3 is predominantly expressed by hematopoietic cells and is highly regulated with cell 
development and activation.  
 
JAK isoform selectivity is dose dependent 
Table 4 showed the IC50 (concentration needed to inhibit 50% of activation) of different 
JAKi. Low IC50 value implies higher potency. JAK isoform selectivity is determined by ratio 
and difference between IC50s for different JAK isoforms. Table 4 showed not IC50 but also 
the ratio of IC50s. One may consider the ratio as the “JAK selectivity dose window”.  
Conventional pharmacology will select compound with high potency. However, in the case 
of JAKi, potency affects JAK selectivity dose window. Highly potent compound will have 
narrow windows whilst low potency compound will have larger selectivity window. 
Therefore, the clinical impact of JAK isoform selectivity is therefore dependent on dose, cell 
type, tissue penetration and genetics of the individual patient. This is probably best 
illustrated by the change in Hb in tofacitinib 5mg-treated patients with less Hb increase in 
the 10mg group.  
 
JAK isoforms as therapeutic targets in RA  
Since JAK isoforms are important in the signal transduction of multiple cytokines, different 
JAKi might inhibit different cytokines, which could be important in tailoring treatment to 
 15 
patients. All current JAKi approved and in development have significant effect on JAK1. Even 
for the “JAK3 selective decernotinib”, the ratio between JAK3 and JAK1 inhibition is only 0.6. 
JAK1 is involved in the signalling transduction of IL-6, interferon and the common gamma-
chain cytokines including IL-2 and IL-15. Amongst these, IL-6 is a proven therapeutic target 
in RA. Some of the side effects associated with IL-6 inhibition such as increase in liver 
transaminases and lipids, neutropenia as well as gastrointestinal perforation are also 
associated with JAKi suggesting inhibiting IL-6 is a significant mode of action. However, JAKi 
differ from IL-6 inhibitors in that CRP whilst reduced did not normalise suggesting that 
inhibition of IL-6 activity is incomplete45. A phase II RCT with very small patient number 
suggested that anti-interferon- may be effective in RA56. Whether interferon suppression is 
an important contributor to the therapeutic benefit of JAK1 inhibitors is unclear. However, 
interferon- is important in anti-viral immunity which is a potential explanation for herpes 
zoster reactivation. Nevertheless, current evidence suggests that JAK1 is an important 
therapeutic target in RA. 
 
Whether JAK2 is a good therapeutic target in RA is less clear. Pro-inflammatory cytokines 
such as GM-CSF signals via JAK2. A phase II RCT of anti-GM-CSF monoclonal antibody 
showed benefit in RA57. A head to head trial suggested of anti-GM-CSF monoclonal 
antibody was as efficacious as TNF inhibitor58. Therefore, inhibiting both JAK1 and JAK2 may 
produce greater anti-inflammatory effect by inhibiting GM-CSF. The disadvantage of 
inhibiting JAK2 is potential side effects associated with inhibiting haematopoetic cytokines 
including erythropoietin, IL-3 and IL-5 and hormones such as prolactin and growth hormone. 
The clinical significance of long-term JAK2 inhibition remains unknown. It will be prudent to 
investigate whether JAK2 inhibition leads to increase in platelet count and the rare cases of 
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DVT/PE. In vitro experiment has shown that JAK2 is involved in platelet activation. JAK2 
inhibitor attenuated collagen-induced platelet aggregation in a dose-dependent manner59, 
so an association between thrombosis and JAK2 via effect on platelet seems 
counterintuitive. Aside from the hitherto unknown effect of JAK2 inhibition and thrombosis, 
small molecule inhibitors, unlike mAbs, are more likely to have off-target side effects that 
may not be associated with JAK inhibition but are compound-specific.  
 
Based on available data, it is unclear whether JAK3 and TYK2 are desirable therapeutic 
targets in RA. 
 
Conclusion 
JAK isoform selectively of JAKi is relative and not absolute. It is dose and tissue dependent. 
Current approved JAKi and those in development significantly inhibit JAK1, which is an 
effective therapeutic target in RA, although herpes zoster reactivation is probably a class 
effect of JAK1 inhibitors. The balance of benefit and risk of inhibiting JAK2, JAK3 and TYK2 is 
uncertain and should be evaluated in the future. The exact role of JAKi in the treatment 
pathway of RA should be further assessed by head-to-head and strategy trials. The 
manufacturing cost of JAKi is substantially less than biologics. With the potential of generic 
JAKi in the future, widen access to more effective treatment for RA is becoming tangible.   
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Table 1: ACR responses at Primary Endpoints in Tofacitinib and Baricitinib RCTs 
 
 Controls JAKi Active comparator 
 ACR20 ACR50 ACR70 ACR20 ACR50 ACR70 ACR20 ACR50 ACR70 
MTX IR          
Oral-
Standard11 
Tofacitinib 
(5mg bid) 
26 7 2 61 34 12 56 24 9 
Oral-
Standard11 
Tofacitinib 
(10mg bid) 
   59 28 15    
RA Beam12 
Barcitinib 
(4mg qd) 
40 17 5 70 45 19 61 35 13 
cDMARD-IR          
Oral-Sync13 
Tofacitinib 
(5mg bid) 
27 10 2 56 27 8    
Oral-Sync13 
Tofacitinib 
(10mg bid) 
   65 34 14    
RA-Build14 
Barcitinib 
(2mg qd) 
39 13 3 66 34 18    
RA-Build14 
Barcitinib 
(4mg qd) 
   62 33 18    
bDMARD-IR          
Oral-Step15 
Tofacitinib 
(5mg bid) 
24 8 2 42 27 14    
Oral-Step15 
Tofacitinib 
(10mg bid) 
   48 28 11    
RA Beacon16 
Barcitinib 
(2mg qd) 
27 8 2 49 20 13    
RA Beacon16 
Barcitinib 
(4mg qd) 
   55 28 11    
MTX naive           
Oral Start20 
Tofacitinib 
(5mg bid) 
51 
(MTX 
as 
control) 
27 
(MTX as 
control) 
12 
(MTX as 
control) 
71 47 26    
Oral Start20 
Tofacitinib 
(10mg bid) 
   76 56 38    
RA-Begin18 
Barcitinib 
(4mg 
62 
(MTX 
as 
43 
(MTX as 
control) 
21 
(MTX as 
control) 
78 63 40    
 19 
qd)+MTX control) 
Monotherapy          
Oral Solo19 
Tofacitinib 
(5mg bid) 
27 13 6 60 31 15    
Oral Solo19 
Tofacitinib 
(10mg bid) 
   66 37 20    
RA-Begin18 
Barcitinib 
(4mg qd) 
62 
(MTX 
as 
control) 
43 
(MTX as 
control) 
21 
(MTX as 
control) 
77 60 42    
  
Legend: Numbers are percentage  
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 Table 2: Results of Phase II RCT of JAKi in Development 
 
  Controls JAKi 
  ACR20 ACR50 ACR70 ACR20 ACR50 ACR70 
JAK1 Selective        
Filgotinib 
DARWIN 124 
(+ MTX) 
 
50mg qd 44 15 8 56 33 16 
 100mg qd    64 38 21 
 200mg qd    69 43 24 
Filgotinib 
DARWIN 225 
(Monotherapy) 
 
50mg qd 29 11 4 67 35 8 
 100mg qd    67 36 19 
 200mg qd    72 43 13 
Upadacitinib 
BALANCE 223  
(MTX-IR) 
6mg bid 46 18 6 68 46 28 
 12mg bid    80 50 16 
 18mg bid    64 40 26 
Upadacitinib 
BALANCE 122 
(TNF-IR) 
6mg bid    58 36 26 
 12mg bid    71 42 22 
 18mg bid    67 38 22 
Moderate 
JAK3 Selective 
       
Dercernotinib29 100md qd 18 7 3 47 23 10 
 150mg qd    67 39 11 
 200mg qd    57 35 10 
 100mg bid    68 39 22 
Dercernotinib 
Monotherapy28 
25mg bid 29 7 2 39 17 7 
 50 mg bid    61 32 12 
 100 mg bid    65 38 18 
 150 mg bid    66 49 22 
Peficitinib27 25mg qd 44 26 11 44 18 9 
 50 mg qd    62 33 15 
 100 mg qd    46 33 17 
 150 mg qd    57 37 19 
Peficitinib26 25mg qd 29 10 8 22 15 7 
 50 mg qd    37 25 16 
 100 mg qd    48 28 19 
 150 mg qd    56 28 11 
Legend: Numbers are percentage. bid: bis in die (twice per day) qd: quaque die (once per day) 
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Table 3: Safety of Tofacitinib and Baricitinib: Incidence Rate per 100 patient years (95% confidence 
intervals) 
 
 Tofacitinib 
(JAK, JAK3) 
Baricitinib 
(JAK1, 
JAK2) 
Peficitinib 
(JAK1, JAK2) 
Fligotinib 
(JAK1) 
Upadacitinib 
(JAK1) 
Decernotinib  
(JAK3) 
Serious Infection 2.7 
(2.5-3.9)  
2.9 
(2.5-3.4) 
    
Herpes Zoster 3-4      
Malignancies 0.9(0.8-1) 0.8 
(0.6-1.0) 
    
Lymphoma 0.1 
(0.1-0.2)  
0.09( 
 0.03-0.19) 
    
Non-melanoma 
skin cancer 
0.6 
(0.5-0.7)  
0.4 
(0.2-0.5) 
    
Gastrointestinal 
perforation 
0.11 
(0.07-0.17) 
0.05( 
 0.01-0.13) 
    
DVT/PE  0.5 
(0.3-0.7) 
    
Changes in Laboratory Tests (mean + SD) 
 
Haemoglobin 
(g/dl) 
+0.47+0.05 
(5mg) 
+0.28+0.05 
(10mg) 
-0.17 Decrease Increase Decreases at 
higher doses 
Increase 
Neutrophil 
(x103/mm3) 
-1.09+0.1 
(5mg) 
-1.49+0.1 
(10mg) 
-1.08 +0.07 Decrease Decrease Decrease  Decrease in 
high dose 
Lymphocyte 
count 
(x103/mm3) 
-0.24+0.03 
(5mg) 
-0.36+0.03 
(10mg) 
-0.01  
(2mg) 
-0.05  
(4mg)  
Decrease No change 
Some 
patients 
developed 
lymphopenia 
Decrease Decrease 
Platelets 
 
-30% Increase Decrease Decrease NR NR 
Liver 
transaminase 
 
Increase up  
 
Increase Increase in 
high dose 
group 
Increase 
 
Increase Increase 
Cholesterol Increase Increase Increase Increase Increase Increase 
Creatinine 
 
Increase Increase) Increase Increase Increase Increase 
Creatinine 
Phosphokinase 
Increase Increase Increase NR Increase Increase 
Legend: Safety data are incidence rate per 100 patient years with 95% confidence intervals. 
Laboratory results are mean + SD unless stated otherwise. NR: Not reported 
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Table 4: In vitro JAK isoform selectivity 
 
 Enzyme essay IC50(nM)    
Compound JAK1 JAK2 JAK3 TyK2 JAK2:JAK
1 
JAK3:JAK1 TyK2:JAK1 
Tofacitinib 15.1 77.4 55.0 489 5.1 3.6 32.4 
Baricitinib 4.0 6.6 787 61 1.5 196.8 15.3 
Filgotinib 363 2400 >10,000 2,600 6.6 >27.5 7.2 
Upadacitinib 8 600 139 NA 75 17.4 NA 
Peficitinib 3.9 5.0 0.7 4.8 1.3 0.2 1.2 
Decernotinib 112 619 74.4 >10,000 5.5 0.67 >89 
Legend: JAK: Janus kinase, IC50: half maximal inhibitory concentration, TyK: Non-receptor 
Tyrosine-protein Kinase 
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Figure 1: Cytokine signalling via JAK isoforms and their inhibitors 
Legend to Figure 1: IL: interleukin, JAK: janus kinase, p: phosphate
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